Table 2.
Bone mineral density and bone metabolic markers in continuing bisphosphonates and switching from bisphosphonates to denosumab groups
| BP‐BP group (n = 10) | BP‐Dmab group (n = 12) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 24‐week | Mean % Change | P‐value (in group) | Baseline | 24‐week | Mean % Change | P‐value (in group) | P‐value (between groups) | |
| LS BMD (g/cm2) | 0.91 ± 0.14 | 0.92 ± 0.15 | 1.8 ± 3.0 | 0.20 | 0.87 ± 0.09 | 0.89 ± 0.09 | 1.7 ± 3.6 | 0.17 | 0.96 |
| FN BMD (g/cm2) | 0.55 ± 0.05 | 0.57 ± 0.02 | 4.6 ± 10.4 | 0.40 | 0.59 ± 0.09 | 0.60 ± 0.09 | 1.6 ± 3.5 | 0.22 | 0.40 |
| BAP (µg/L) | 6.5 ± 0.9 | 6.6 ± 1.0 | 2.4 ± 13.9 | 0.83 | 9.8 ± 2.1 | 8.6 ± 2.7 | −13.7 ± 12.3 | 0.01 | 0.03 |
| TRACP‐5b (mU/dL) | 156.5 ± 68.8 | 166.2 ± 41.8 | 29.5 ± 16.1 | 0.02 | 173.5 ± 82.1 | 178.7 ± 89.9 | 4.4 ± 22.9 | 0.73 | 0.04 |
| Pentosidine (μg/mL) | 0.058 ± 0.029 | 0.087 ± 0.043 | 69.6 ± 96.6 | 0.17 | 0.054 ± 0.025 | 0.063 ± 0.023 | 42.0 ± 74.3 | 0.41 | 0.62 |
| ucOC (ng/mL) | 1.1 ± 0.5 | 1.4 ± 0.7 | 54.4 ± 82.5 | 0.36 | 1.4 ± 0.8 | 1.1 ± 0.4 | −11.3 ± 25.0 | 0.07 | 0.05 |
Data are reported as the mean ± standard deviation. P‐value (in group): baseline versus 24 weeks in each group. P‐value (between groups): comparisons in mean percentage change between continuing bisphosphonates (BP‐BP) and switching from bisphosphonates to denosumab (BP‐Dmab) groups. BAP, bone‐specific alkaline phosphatase; BMD, bone mineral density; BP, bisphosphonate; Dmab, denosumab; FN, femoral neck; LS, lumber spine; TRACP‐5b, tartrate‐resistant acid phosphatase 5b; ucOC, undercarboxylated osteocalcin.